Cargando…
Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulati...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638102/ https://www.ncbi.nlm.nih.gov/pubmed/36353562 http://dx.doi.org/10.3389/fonc.2022.1045995 |
_version_ | 1784825333939175424 |
---|---|
author | Muendlein, Axel Severgnini, Luciano Decker, Thomas Heinzle, Christine Leiherer, Andreas Geiger, Kathrin Drexel, Heinz Winder, Thomas Reimann, Patrick Mayer, Frank Nonnenbroich, Christoph Dechow, Tobias |
author_facet | Muendlein, Axel Severgnini, Luciano Decker, Thomas Heinzle, Christine Leiherer, Andreas Geiger, Kathrin Drexel, Heinz Winder, Thomas Reimann, Patrick Mayer, Frank Nonnenbroich, Christoph Dechow, Tobias |
author_sort | Muendlein, Axel |
collection | PubMed |
description | Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients. |
format | Online Article Text |
id | pubmed-9638102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96381022022-11-08 Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients Muendlein, Axel Severgnini, Luciano Decker, Thomas Heinzle, Christine Leiherer, Andreas Geiger, Kathrin Drexel, Heinz Winder, Thomas Reimann, Patrick Mayer, Frank Nonnenbroich, Christoph Dechow, Tobias Front Oncol Oncology Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638102/ /pubmed/36353562 http://dx.doi.org/10.3389/fonc.2022.1045995 Text en Copyright © 2022 Muendlein, Severgnini, Decker, Heinzle, Leiherer, Geiger, Drexel, Winder, Reimann, Mayer, Nonnenbroich and Dechow https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Muendlein, Axel Severgnini, Luciano Decker, Thomas Heinzle, Christine Leiherer, Andreas Geiger, Kathrin Drexel, Heinz Winder, Thomas Reimann, Patrick Mayer, Frank Nonnenbroich, Christoph Dechow, Tobias Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title_full | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title_fullStr | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title_full_unstemmed | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title_short | Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
title_sort | circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638102/ https://www.ncbi.nlm.nih.gov/pubmed/36353562 http://dx.doi.org/10.3389/fonc.2022.1045995 |
work_keys_str_mv | AT muendleinaxel circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT severgniniluciano circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT deckerthomas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT heinzlechristine circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT leihererandreas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT geigerkathrin circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT drexelheinz circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT winderthomas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT reimannpatrick circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT mayerfrank circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT nonnenbroichchristoph circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients AT dechowtobias circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients |